Status:

COMPLETED

Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant

Lead Sponsor:

OHSU Knight Cancer Institute

Conditions:

Cancer

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

RATIONALE: Antiemetic drugs, such as aprepitant, ondansetron, and dexamethasone, may help lessen or prevent nausea and vomiting in patients undergoing a stem cell transplant. PURPOSE: This randomized...

Detailed Description

OBJECTIVES: Primary * Compare the efficacy of standard antiemetic therapy comprising ondansetron and dexamethasone combined with either aprepitant or placebo in controlling nausea and vomiting, as d...

Eligibility Criteria

Inclusion

  • Inclusion:
  • 18 years of age or greater
  • must be scheduled for an autologous or allogeneic bone marrow or peripheral stem cell transplant
  • Eastern Cooperative Oncology Group(ECOG) performance status \< or = 2
  • patients must have signed informed consent
  • must be able to swallow tablets and capsules
  • must be receiving a cyclophosphamide containing regimen.
  • Exclusion:
  • patient has known sensitivity to aprepitant, ondansetron, or dexamethasone
  • patient has received another investigational drug in the past 30 days
  • patient has had emesis or requires antiemetic agents in the 48 hours prior to beginning conditioning therapy
  • patient has taken neurokinin-1 antagonists for 14 days prior to enrollment
  • patient is pregnant, has a positive serum human chorionic gonadotropin(hCg) or is lactating
  • patient has serum creatinine level \> or = 2\*ULN
  • patient has severe hepatic insufficiency (Child-Pugh score \>9)
  • patient drinks \> 5 drinks/day for the last year
  • patient with concurrent illness requiring systemic corticosteroid use other than planned dexamethasone during conditioning therapy

Exclusion

    Key Trial Info

    Start Date :

    May 1 2004

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    January 1 2009

    Estimated Enrollment :

    40 Patients enrolled

    Trial Details

    Trial ID

    NCT00248547

    Start Date

    May 1 2004

    End Date

    January 1 2009

    Last Update

    May 9 2017

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    OHSU Knight Cancer Institute

    Portland, Oregon, United States, 97239-3098